MorphoSys shares plunge after partner Roche says Alzheimer’s drug trials didn’t meet goals


German-listed shares of MorphoSys MOR, -32.03% MOR, +2.44% lost a third of their value on Monday after its partner Roche said an Alzheimer drug trial failed. Roche ROG, -3.58% slumped 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia did not meet their primary endpoint of slowing clinical decline.

This article was originally published by Read the original article here.

Previous articleDow Jones Newswires: Rheinmetall to acquire Spanish ammunition maker Expal for $1.24 billion
Next articleRussian foreign minister hospitalized at G20 meeting


Please enter your comment!
Please enter your name here